1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Prothymosin alpha (PTMα) is a small acidic polypeptide from the thymosin family with immune activity and protective properties against oxidative stress induced by reactive oxygen species trimethylamine-N-oxide (TMAO), produced in the liver from gut bacterial metabolite trimethylamine and associated with increased cardiovascular disease risk and higher all-cause mortality. Ischemia-modified albumin (IMA) is a significant oxidative stress biomarker, particularly in ischemia-reperfusion conditions. This study investigates PTMα, TMAO, and IMA levels in type 2 diabetes mellitus (T2DM) patients, both with and without hyperlipidemia, to explore their relationships and their potential role as biomarkers or therapeutic targets.

The study received ethical approval from the Selcuk University Faculty of Medicine Hospital committee under approval number 2024/33. The study included male and female T2DM patients aged 30–60, with 30 having hyperlipidemia and the rest being non-lipemic. TMAO was performed using API 3200 LC-MS\MS while PTMα was analyzed using an ELISA kit from BT LAB, serum IMA levels were evaluated by the spectrophotometric method.

Comparisons were made between those with T2DM and control groups. In the T2DM group, PTMα was significantly higher in females ( = 0.047), while TMAO and IMA showed no significant gender difference. The control group had no significant differences in PTMα, TMAO, and IMA levels. Comparisons among healthy controls, non-lipemic T2DM patients, and hyperlipidemic T2DM patients revealed significantly decreased PTMα levels with no change in IMA levels across groups. In contrast, TMAO was significantly higher in the patient group.

The findings of this study have potential implications for the field, suggesting that PTMα might serve as a prognostic indicator for T2DM and that reduced TMAO levels might play a role in T2DM pathogenesis, opening up new avenues for research and treatment.

© 2025 Gharab, Bik, Atta, Jawad, Almaghrebi, Salman, et al., licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.39
2025-06-30
2025-07-16
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.39.html?itemId=/content/journals/10.5339/qmj.2025.39&mimeType=html&fmt=ahah

References

  1. Tomic D, Shaw JE. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022; 18:(9)525–39.
    [Google Scholar]
  2. Goyal R, Jialal I. Diabetes mellitus type 2. StatPearls Publishing, Treasure Island (FL). 2018.
    [Google Scholar]
  3. Abed BA, Al-AAraji SB. Estimation of Galanin hormone in patients with newly thyroid dysfunction in type 2 diabetes mellitus. Biochem Cell Arch. 2021; 21:(1)1317–21.
    [Google Scholar]
  4. Lefta N, Abed A. Estimation of asprosin levels in female Iraqi patients with type 2 diabetes and hypothyroidism. J Med Chem Sci. 2023; 6:(2)433–9.
    [Google Scholar]
  5. Lee S-H, Park S-Y. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022; 46:(1)15–37.
    [Google Scholar]
  6. Mahemuti N, Jing X. Association between systemic immunity-inflammation index and hyperlipidemia: a population-based study from the NHANES (2015-2020). Nutrients. 2023; 15:(5)1177.
    [Google Scholar]
  7. Samara P, Ioannou K. Prothymosin alpha and immune responses: are we close to potential clinical applications?Vit Horm. 2016; 102:: 179–207.
    [Google Scholar]
  8. Karachaliou C-E, Kostopoulos IV. Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential. Heliyon. 2019; 5:(10)e02616.
    [Google Scholar]
  9. Samara P, Ioannou K. The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro. Int Immunopharmacol. 2013; 15:(1)50–7.
    [Google Scholar]
  10. Piñeiro A, Cordero OJ. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides. 2000; 21:(9)1433–46.
    [Google Scholar]
  11. Greco M, Mirabelli M. Prothymosin-Alpha, a novel and sensitive biomarker of the inflammatory and insulin-resistant statuses of obese individuals: a pilot study involving humans. Endocrines. 2023; 4:(2)427–36.
    [Google Scholar]
  12. Wu H-T, Kang L. Prothymosin α activates type I collagen to develop a fibrotic placenta in gestational diabetes. Clin Sci. 2020; 134:(18)2435–45.
    [Google Scholar]
  13. Birmpilis AI, Paschalis A. Immunogenic cell death, damps and prothymosin α as a putative anticancer immune response biomarker. Cells. 2022; 11:(9)1415.
    [Google Scholar]
  14. Su Y-C, Ou H-Y. Prothymosin-α overexpression contributes to the development of insulin resistance. J Clin Endocrinol Metab. 2015; 100:(11)4114–23.
    [Google Scholar]
  15. Ueda H. Prothymosin α plays role as a brain guardian through Ecto-F1 ATPase-P2Y12 complex and TLR4/MD2. Cells. 2023; 12:(3)496.
    [Google Scholar]
  16. Jalandra R, Dalal N. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer. Appl Microbiol Biotechnol. 2021;(105)1–10.
    [Google Scholar]
  17. Thomas MS, Fernandez ML. Trimethylamine N-oxide (TMAO), diet and cardiovascular disease. Curr Atheroscler Rep. 2021; 23:: 1–7.
    [Google Scholar]
  18. Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021; 20:: 301.
    [Google Scholar]
  19. Liu W, Wang C. Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy. Acta Diabetol. 2021; 58:: 221–9.
    [Google Scholar]
  20. Shevtsova A, Gordiienko I. Ischemia-modified albumin: origins and clinical implications. Dis Markers. 2021; 2021:: 1–18.
    [Google Scholar]
  21. Sbarouni E, Georgiadou P. Ischemia modified albumin: is this marker of ischemia ready for prime time use. Hellenic J Cardiol. 2008; 49:(4)260–6.
    [Google Scholar]
  22. Kaefer M, Piva SJ. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010; 43:(4-5)450–4.
    [Google Scholar]
  23. Arzouki NA, AL-Khateeb SM. Assessment the diagnostic value of ischemia modified albumin as a biomarker for prediction of diabetic nephropathy. Biochem Cell Arch. 2020; 20:(2)6311.
    [Google Scholar]
  24. Onmaz DE, Sivrikaya A. The relationship between DAS-28 score and oxidative stress markers in rheumatoid arthritis.
    [Google Scholar]
  25. S¸engül F, Akyürek F. Evaluation of trimethylamine N-oxide (TMAO) levels in blunt thoracic trauma: an experimental study. Genel Tıp Dergisi. 34:(3)327–31.
    [Google Scholar]
  26. Demir S, Nawroth PP. Emerging targets in type 2 diabetes and diabetic complications. Adv Sci. 2021; 8:(18)2100275.
    [Google Scholar]
  27. Scheithauer TP, Rampanelli E. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020; 11:: 571731.
    [Google Scholar]
  28. Caturano A, D’Angelo M. Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications. Curr Issues Mol Biol. 2023; 45:(8)6651–66.
    [Google Scholar]
  29. Ufnal M, Zadlo A. TMAO: a small molecule of great expectations. Nutrition. 2015; 31:(11-12)1317–23.
    [Google Scholar]
  30. Li S-Y, Chen S. Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study. J Transl Med. 2022; 20:(1)374.
    [Google Scholar]
  31. Kalagi NA, Thota RN. Association between plasma trimethylamine N-oxide levels and type 2 diabetes: a case control study. Nutrients. 2022; 14:(10)2093.
    [Google Scholar]
  32. Gao X, Liu X. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014; 118:(4)476–81.
    [Google Scholar]
  33. Lever M, George PM. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS One. 2014; 9:(12)e114969.
    [Google Scholar]
  34. Onmaz DE, Sivrikaya A, Abus¸og˘lu S, Yılmaz S, Ünlü A. Romatoid Artritte DAS-28 Skoru ile Oksidatif Stres Belirteçleri Arasındaki İlis¸ki. Türk Klinik Biyokimya Derg. 2021; 19:(3)200–11.
    [Google Scholar]
  35. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019; 11:(3)45.
    [Google Scholar]
/content/journals/10.5339/qmj.2025.39
Loading
Evaluation of prothymosin alpha, trimethylamine-N-oxide, and ischemia-modified albumin in type 2 diabetes mellitus patients with dysregulated lipid profile
Qatar Medical Journal 2025, 39 (2025); https://doi.org/10.5339/qmj.2025.39
/content/journals/10.5339/qmj.2025.39
/content/journals/10.5339/qmj.2025.39
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Diabetes mellitus, hyperlipidemia, ischemia-modified albumin, prothymosin alpha and trimethylamine-N-oxide

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error